Final report of the OLYMPUS Jelmyto trial: Takeaways for urologists
“I think that these data firmly establish UGN-101, or Jelmyto, as a bona fide treatment option for kidney preservation for patients with low-grade, non-invasive urothelial cancer in the upper urinary tract,” says Seth P. Lerner, MD.
In this video, Seth P. Lerner, MD, gives the final results of the phase 3 OLYMPUS trial, which studied the efficacy of mitomycin-containing reverse thermal gel (UGN-101; Jelmyto) in patients with upper tract urothelial carcinoma and supported the FDA approval of the treatment in this setting.
Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
